Dent Neurologic

DENTNeuro_White

Fran M. Gengo

PharmD

Dr. Gengo serves as Director of Neuropharmacology and the Research Director for the Acute Stroke Treatment Program at DENT, as well as the the Chief Science Officer for DENT’s research affiliate, DNRC. Dr. Gengo is also the Neuropharmacological Director for the DENT Cannabis Clinic.

 

Dr. Gengo is located at DENT Tower in Amherst.

He is currently involved in several protocols of thrombolytics and neuroprotective agents. In addition, he is an Associate Professor of Pharmacy and Neurology and a Clinical Assistant Professor of Neurosurgery at the SUNY at Buffalo School of Medicine.

Dr. Gengo has published numerous papers on the effects of various drugs on the central nervous system and his research entails abstraction and statistical analysis of data acquired from several modalities.

SPECIALITIES

- Neurology
- Neuropharmacology
- Pharmacotherapy

Board Certifications​

- 2005 Neurology
- 2011 Neuroimaging
- 2016 Neurology

Publications

See publications for Fran M. Gengo, PharmD

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with DENT Neurologic Institute)

Titles

- Director of Neuropharmacology
- Research Director, DENT Acute Stroke Treatment Program
- Chief Science Officer, DENT’s research affiliate, DNRC.
- Neuropharmacological Director, DENT Cannabis Clinic.
- Associate Professor of Pharmacy and Neurology, SUNY at Buffalo School of Medicine
- Clinical Assistant Professor of Neurosurgery, SUNY at Buffalo School of Medicine.

Education

Medical / Graduate Education
Philadelphia College of Pharmacy and Science, Philadelphia, PA

Fellowship
SUNY at Buffalo, Department of Pharmaceutics, Buffalo, NY – Pharmacokinetics and Biopharmaceutics

Open Clinical Trials

Alzheimer's

ADNI3 Trial

ADNI3 Trial Dent is taking part in an observational study called the ADNI3 Trial. This historic study of brain aging could help change the future …

Read More →
Alzheimer's

RETHINK-ALZ

Simufilam 100 mg for Mild to Moderate Alzheimer’s Disease

Read More →
Dizziness and Balance

Hearing Aid Research

Hearing Aid Research Are you interested in participating in hearing aid research?  Dr. Zhang is collaborating with Dr. Wei Sun at UB and is recruiting …

Read More →
Headache/Migraine

CGBG Study

We are looking for adults ages 18 to 55 who have been diagnosed with migraine. The CGBC Study will consist of five visits over a period of up to five weeks.

Read More →
Parkisons Disease

PADOVA

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease

Read More →
Epilepsy

STARS and STARS Extension

Studies to Assess the Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Read More →
Alzheimer's

PIONEER T3D: Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate Alzheimer’s Disease Subjects

PIONEER T3D: Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate Alzheimer’s Disease Subjects Inclusion Criteria Age 55-90 years Have a reliable study partner, …

Read More →
ALS

MT-1186-A02

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

Read More →
Alzheimer's

ENVISION

ENVISION Trial  The objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as …

Read More →
Alzheimer's

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3)

The Alzheimer’s Disease Neuroimaging Initiative (also known as ADNI) is a historic study of brain aging looking to help change the future for this disease.

Read More →
Dizziness and Balance

Meniere’s Study

Meniere’s Study Have you been diagnosed with Meniere’s Disease? Do you frequently experience vertigo? If you answered yes to these questions and are over the …

Read More →
Treatment-Resistant Depression

RECOVER VNS

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Read More →
Parkisons Disease

PROSEEK

PROSEEK To Potentially Help Slow Progression for People with Early-stage Parkinson’s Disease The PROSEEK Study is a clinical research study evaluating a once-daily investigational drug …

Read More →
Alzheimer's

Signal – AD

Signal- AD Trial The purpose of the study is to investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in people with …

Read More →
Alzheimer's

ADNI4 Trial

ADNI4 Trial The ADNI4 is multi-center, a non-randomized, natural history, non-treatment study. 1,150 participants will be enrolled across three cohorts: cognitively normal (CN), mild cognitive …

Read More →

Want to participate in a study?

Fill out the form below and one of our Research Coordinators will be in contact with you as soon as possible. If we currently do not have a study that is currently available for you, we will add you to our database for future studies.

Subscribe To Our Newsletter

Sign up to receive email updates on announcements, new services added, company updates & more!

Call us to schedule an appointment

Our entire team, from customer service to patient providers, is focused on the central mission to deliver superior clinical care, advanced neurodiagnostics, clinical research and education that will assist our patients in maximizing their quality of life. We strive to exceed the expectations of our patients, clinical partnerships and community partners.

Scroll to Top